There is opportunity for orthopedic companies to create partnerships with surgeons, department leadership and executive administration. Three leaders share how.
Companies spoke about the need for navigation, robotics and AI at NASS 2024.
Outpatient surgery is the vanguard of modern healthcare and the future of surgical and medical innovation, says an ASC investor.
Certain IP assets related to Sites Medical’s OsteoSync titanium pads will be used to develop next-gen PEEK interbody fusion devices.
The Nevro1 implant is an FDA 510(k)-cleared device intended to transfix the SI joint for immediate stability and long-term fusion.
Stryker divested the majority of its spinal implant business while Zimmer Biomet agreed to acquire foot-and-ankle player Paragon 28.
Paragon 28 has a suite of surgical offerings and product systems spanning all major foot and ankle segments, including fracture and trauma, deformity correction and joint replacement.
The U.S. implants business will be sold to Viscogliosi Brothers. Plans follow to sell the related international spine business.
We preview top trends in orthopedic outpatient surgery for 2025 and recommendations for device companies on how to navigate and respond.
Here’s a look at activity that occurred within the fourth quarter that will support growth in this well-performing segment for the coming year.
The agreement addresses i-FACTOR Bone Graft Putty and FLEX FR products for use in spine procedures in the UK and Ireland.
Agreements include a distribution contract for SAFE Orthopaedics’ implants and instruments and a production contract for development of future products.
Locate Bio, a UK-based regenerative medicine startup, believes it has solved the challenges associated with rhBMP-2 when healing fractures.
Tri-State Biologics will commercialize the RemeOs screw in the U.S. civilian hospital market.
J&J MedTech entered an exclusive U.S. commercial distribution agreement with Responsive Arthroscopy, enhancing its soft tissue portfolio.
The collaboration supports development and clinical deployment of OsteoSight, technology designed for the early identification of low bone mineral density.
The collaboration will promote Osteopore’s off-the-shelf products in Singapore for bone loss treatments in upper and lower extremities.
Anika plans to focus on its core hyaluronic acid technology and advance its differentiated Regenerative Solutions portfolio.
Login
Register for a free account
As a guest member you get access to more articles and videos every month.